业务
货币单位:美元
2025/FY
名称营收比例
Development and commercialization of icosapent ethyl (VASCEPA)2.14亿100.00%
地区
货币单位:美元
2025/FY
名称营收比例
US product revenue, net1.54亿72.15%
许可和特许权使用费收入3,089.3万14.46%
Europe product revenue, net1,837.3万8.60%
Rest of World (RoW) product revenue, net1,024万4.79%